"In the land of the blind, the one-eyed man is king."[7] More drug programs would be improved or saved, thereby fundamentally shifting CNS drug R&D economics relative to pharmaceutical companies that do not fully integrate QSP computational modeling. B Pharmaceutical research and development (R&D) relies on developing good systemic hypotheses about the effect of novel drug mechanisms on pathophysiology. Even if these isolated questions could be satisfactorily answered via QSP computational modeling, a broader application of the modeling to more general questions about the disease is not initiated, and single, isolated modeling attempts prevail. [Extracted from the article]